ReproCELL Incorporated [4978.T]
TOKYO, May 14 (Pulse News Wire) – ReproCELL Incorporated (4978.T) reported lower revenue and profits for the fiscal year ended March 31, 2026, compared to the previous fiscal year. For the fiscal year ending March 31, 2026, ReproCELL's revenue was ¥623 million, down from ¥960 million in the prior fiscal year.
Operating profit was ¥-609 million from ¥-400 million, while ordinary profit decreased to ¥-331 million from ¥-284 million. Net income per share declined to ¥-3.58 from ¥-3.29. The decline in revenue was primarily due to budget constraints among key customers, particularly research institutions in the United States, which led to reduced orders and delayed spending.
Specifically, sales of clinical iPS cells and related services in the medical sector significantly underperformed expectations. Additionally, changes in product mix contributed to the decrease in operating profit. As a result, ReproCELL experienced a substantial difference in performance metrics compared to the previous fiscal year.
🟢 Confidence: High AI-translated content.